Cargando…

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

OBJECTIVE: Use of growth hormone is associated with side effects, including insulin resistance. The objective of this study was to determine whether tesamorelin, a stabilized growth hormone-releasing hormone analogue, would alter insulin sensitivity or control of diabetes. DESIGN: A 12-week randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clemmons, David R., Miller, Sam, Mamputu, Jean-Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/ https://www.ncbi.nlm.nih.gov/pubmed/28617838 http://dx.doi.org/10.1371/journal.pone.0179538

Ejemplares similares

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat
por: Mangili, Alexandra, et al.
Publicado: (2015)

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
por: Bedimo, Roger
Publicado: (2011)

Tesamorelin: A hope for ART-induced lipodystrophy
por: Patel, Akash, et al.
Publicado: (2011)

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
por: Fourman, Lindsay T., et al.
Publicado: (2020)

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
por: Rahman, Farah, et al.
Publicado: (2022)

935. Effect of Tesamorelin in People with HIV with and without Dorsocervical Fat: Post Hoc Analysis of Phase III Double Blind Placebo Control Trial
por: Rahman, Farah, et al.
Publicado: (2020)

Growth Hormone-Releasing Hormone and Its Analogues: Significance for MSCs-Mediated Angiogenesis
por: Xia, Xiangyang, et al.
Publicado: (2016)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV
por: McLaughlin, Taryn, et al.
Publicado: (2023)

Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach
por: Fourman, Lindsay T., et al.
Publicado: (2021)

Efficacy and safety of a 4-year combination therapy of growth hormone and gonadotropin-releasing hormone analogue in pubertal girls with short predicted adult height
por: Dotremont, Hilde, et al.
Publicado: (2023)

Growth Hormone-Releasing Hormone in Diabetes
por: Fridlyand, Leonid E., et al.
Publicado: (2016)

Early preclinical work with gonadotropin-releasing hormone analogues
por: Gordon, Keith
Publicado: (2023)

Gonadotropin-releasing hormone analogue and recombinant human growth hormone treatment for idiopathic central precocious puberty in girls
por: Shi, Yuzhen, et al.
Publicado: (2022)

Structural Motif Descriptors as a Way To Elucidate the Agonistic or Antagonistic Activity of Growth Hormone–Releasing Hormone Peptide Analogues
por: Jeanne Dit Fouque, Kevin, et al.
Publicado: (2018)

Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues
por: Yuen, Kevin C. J., et al.
Publicado: (2021)

Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria
por: Brik, Tessa, et al.
Publicado: (2020)

Efficacy and Safety of Sustained-Release Recombinant Human Growth Hormone in Korean Adults with Growth Hormone Deficiency
por: Kim, Youngsook, et al.
Publicado: (2014)

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
por: Ahmann, A., et al.
Publicado: (2015)

Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
por: Kaufmann, M.
Publicado: (1998)

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
por: Jonat, W.
Publicado: (1998)

A Case of Cyclic Vomiting Syndrome Responding to Gonadotropin-Releasing Hormone Analogue
por: Shin, Young Kook, et al.
Publicado: (2010)

Anaphylactic reaction to gonadotropin‐releasing hormone analogues: a pediatric case report
por: Ricci, Franco, et al.
Publicado: (2018)

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2022)

Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2023)

Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats.
por: Maynard, P. V., et al.
Publicado: (1979)

Bilateral injection-site granuloma by subcutaneous administration of luteinizing hormone-releasing hormone analogue: a case report
por: Kitazawa, Riko, et al.
Publicado: (2009)

The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
por: Milecki, Tomasz, et al.
Publicado: (2014)

Effects of Gonadotropin-Releasing Hormone (GnRH) and Its Analogues on the Physiological Behaviors and Hormone Content of Tetrahymena pyriformis
por: Lajkó, Eszter, et al.
Publicado: (2019)

Association of Gonadotropin-Releasing Hormone Analogue Use With Subsequent Use of Gender-Affirming Hormones Among Transgender Adolescents
por: Nos, Andrea L., et al.
Publicado: (2022)

The Anticancer Activity Compared Between Triptorelin and a New Gonadotropin Releasing Hormone Analogue
por: Saleh-Abady, Mohammad Mirzaei, et al.
Publicado: (2009)

Gonadotropin-Releasing Hormone Analogue Stimulation Test Versus Venous Sampling in Postmenopausal Hyperandrogenism
por: Tng, Eng-Loon, et al.
Publicado: (2020)

Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance
por: Huang-Doran, Isabel, et al.
Publicado: (2021)

Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine
por: Saleh, Farrah L., et al.
Publicado: (2023)

Effect of growth hormone releasing hormone on chondrocytes of osteoarthritis
por: LI, Zhuoran, et al.
Publicado: (2022)

Physiological and metabolic characteristics of novel double‐mutant female mice with targeted disruption of both growth hormone‐releasing hormone and growth hormone receptor
por: Icyuz, Mert, et al.
Publicado: (2021)

Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly
por: Clemmons, David R., et al.
Publicado: (2023)

Repetitive Stimulation of the Pituitary with Growth-Hormone-Releasing Hormone Alters the Proportion of 22 and 20 Kilodalton Human-Growth Hormone Released
por: Webb, Emma A., et al.
Publicado: (2010)

Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient Little mice
por: Peroni, Cibele N., et al.
Publicado: (2012)

Thyroid Hormone Analogues: An Update
por: Zucchi, Riccardo
Publicado: (2020)

The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.
por: Wängberg, B., et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_bj058btqov8t2mkjknh8kefo48